Taysha Secures Licence for UT Southwestern’s CLN7 Gene Therapy
Taysha Gene Therapies has secured an exclusive option from the University of Texas Southwestern (UTSW) to license worldwide rights to a clinical-stage gene therapy program for CLN7 disease, a form of late-infantile Batten disease. A first-generation CLN7 therapy is currently being evaluated in a Phase 1 clinical trial…